{"organizations": [], "uuid": "d0bf9bd65a702e87b976a4f590e756f9c40314c3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-regeneron-says-fda-to-conduct-prio/brief-regeneron-says-fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-idUSASC09Y4T", "country": "US", "domain_rank": 408, "title": "BRIEF-Regeneron Says FDA To Conduct Priority Review Of Cemiplimab As A Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T09:16:00.000+03:00", "replies_count": 0, "uuid": "d0bf9bd65a702e87b976a4f590e756f9c40314c3"}, "author": "", "url": "https://www.reuters.com/article/brief-regeneron-says-fda-to-conduct-prio/brief-regeneron-says-fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-idUSASC09Y4T", "ord_in_thread": 0, "title": "BRIEF-Regeneron Says FDA To Conduct Priority Review Of Cemiplimab As A Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma", "locations": [], "entities": {"persons": [{"name": "pri", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "fda to conduct priority review of cemiplimab", "sentiment": "negative"}, {"name": "advanced cutaneous squamous cell carcinoma reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "regeneron pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News April 30, 2018 / 6:19 AM / Updated 3 minutes ago BRIEF-Regeneron Says FDA To Conduct Priority Review Of Cemiplimab As A Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma Reuters Staff 1 Min Read\nApril 30 (Reuters) - Regeneron Pharmaceuticals Inc:\n* FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA\n* SAYS TARGET ACTION DATE FOR FDA DECISION IS OCTOBER 28, 2018. Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-30T09:16:00.000+03:00", "crawled": "2018-04-30T09:23:54.000+03:00", "highlightTitle": ""}